Cargando…
Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience
BACKGROUND: The optimal treatment for recurrent high-grade gliomas (rHGGs) remains uncertain. This study aimed to investigate the efficacy and safety of hypofractionated stereotactic radiosurgery (HSRS) as a first-line salvage treatment for in-field recurrence of high-grade gliomas. METHODS: Between...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863415/ https://www.ncbi.nlm.nih.gov/pubmed/33546642 http://dx.doi.org/10.1186/s12885-021-07856-y |
_version_ | 1783647489525547008 |
---|---|
author | Guan, Yun Xiong, Ji Pan, Mingyuan Shi, Wenyin Li, Jing Zhu, Huaguang Gong, Xiu Li, Chao Mei, Guanghai Liu, Xiaoxia Pan, Li Dai, Jiazhong Wang, Yang Wang, Enmin Wang, Xin |
author_facet | Guan, Yun Xiong, Ji Pan, Mingyuan Shi, Wenyin Li, Jing Zhu, Huaguang Gong, Xiu Li, Chao Mei, Guanghai Liu, Xiaoxia Pan, Li Dai, Jiazhong Wang, Yang Wang, Enmin Wang, Xin |
author_sort | Guan, Yun |
collection | PubMed |
description | BACKGROUND: The optimal treatment for recurrent high-grade gliomas (rHGGs) remains uncertain. This study aimed to investigate the efficacy and safety of hypofractionated stereotactic radiosurgery (HSRS) as a first-line salvage treatment for in-field recurrence of high-grade gliomas. METHODS: Between January 2016 and October 2019, 70 patients with rHGG who underwent HSRS were retrospectively analysed. The primary endpoint was overall survival (OS), and secondary endpoints included both progression-free survival (PFS) and adverse events, which were assessed according to Common Toxicity Criteria Adverse Events (CTCAE) version 5. The prognostic value of key clinical features (age, performance status, planning target volume, dose, use of bevacizumab) was evaluated. RESULTS: A total of 70 patients were included in the study. Forty patients were male and 30 were female. Forty-nine had an initial diagnosis of glioblastoma (GBM), and the rest (21) were confirmed to be WHO grade 3 gliomas. The median planning target volume (PTV) was 16.68 cm(3) (0.81–121.96 cm(3)). The median prescribed dose was 24 Gy (12–30 Gy) in 4 fractions (2–6 fractions). The median baseline of Karnofsky Performance Status (KPS) was 70 (40–90). With a median follow-up of 12.1 months, the median overall survival after salvage treatment was 17.6 months (19.5 and 14.6 months for grade 3 and 4 gliomas, respectively; p = .039). No grade 3 or higher toxicities was recorded. Multivariate analysis showed that concurrent bevacizumab with radiosurgery and KPS > 70 were favourable prognostic factors for grade 4 patients with HGG. CONCLUSIONS: Salvage HSRS showed a favourable outcome and acceptable toxicity for rHGG. A prospective phase II study (NCT04197492) is ongoing to further investigate the value of hypofractionated stereotactic radiosurgery (HSRS) in rHGG. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-07856-y. |
format | Online Article Text |
id | pubmed-7863415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78634152021-02-05 Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience Guan, Yun Xiong, Ji Pan, Mingyuan Shi, Wenyin Li, Jing Zhu, Huaguang Gong, Xiu Li, Chao Mei, Guanghai Liu, Xiaoxia Pan, Li Dai, Jiazhong Wang, Yang Wang, Enmin Wang, Xin BMC Cancer Research Article BACKGROUND: The optimal treatment for recurrent high-grade gliomas (rHGGs) remains uncertain. This study aimed to investigate the efficacy and safety of hypofractionated stereotactic radiosurgery (HSRS) as a first-line salvage treatment for in-field recurrence of high-grade gliomas. METHODS: Between January 2016 and October 2019, 70 patients with rHGG who underwent HSRS were retrospectively analysed. The primary endpoint was overall survival (OS), and secondary endpoints included both progression-free survival (PFS) and adverse events, which were assessed according to Common Toxicity Criteria Adverse Events (CTCAE) version 5. The prognostic value of key clinical features (age, performance status, planning target volume, dose, use of bevacizumab) was evaluated. RESULTS: A total of 70 patients were included in the study. Forty patients were male and 30 were female. Forty-nine had an initial diagnosis of glioblastoma (GBM), and the rest (21) were confirmed to be WHO grade 3 gliomas. The median planning target volume (PTV) was 16.68 cm(3) (0.81–121.96 cm(3)). The median prescribed dose was 24 Gy (12–30 Gy) in 4 fractions (2–6 fractions). The median baseline of Karnofsky Performance Status (KPS) was 70 (40–90). With a median follow-up of 12.1 months, the median overall survival after salvage treatment was 17.6 months (19.5 and 14.6 months for grade 3 and 4 gliomas, respectively; p = .039). No grade 3 or higher toxicities was recorded. Multivariate analysis showed that concurrent bevacizumab with radiosurgery and KPS > 70 were favourable prognostic factors for grade 4 patients with HGG. CONCLUSIONS: Salvage HSRS showed a favourable outcome and acceptable toxicity for rHGG. A prospective phase II study (NCT04197492) is ongoing to further investigate the value of hypofractionated stereotactic radiosurgery (HSRS) in rHGG. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-07856-y. BioMed Central 2021-02-05 /pmc/articles/PMC7863415/ /pubmed/33546642 http://dx.doi.org/10.1186/s12885-021-07856-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Guan, Yun Xiong, Ji Pan, Mingyuan Shi, Wenyin Li, Jing Zhu, Huaguang Gong, Xiu Li, Chao Mei, Guanghai Liu, Xiaoxia Pan, Li Dai, Jiazhong Wang, Yang Wang, Enmin Wang, Xin Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience |
title | Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience |
title_full | Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience |
title_fullStr | Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience |
title_full_unstemmed | Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience |
title_short | Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience |
title_sort | safety and efficacy of hypofractionated stereotactic radiosurgery for high-grade gliomas at first recurrence: a single-center experience |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863415/ https://www.ncbi.nlm.nih.gov/pubmed/33546642 http://dx.doi.org/10.1186/s12885-021-07856-y |
work_keys_str_mv | AT guanyun safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT xiongji safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT panmingyuan safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT shiwenyin safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT lijing safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT zhuhuaguang safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT gongxiu safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT lichao safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT meiguanghai safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT liuxiaoxia safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT panli safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT daijiazhong safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT wangyang safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT wangenmin safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience AT wangxin safetyandefficacyofhypofractionatedstereotacticradiosurgeryforhighgradegliomasatfirstrecurrenceasinglecenterexperience |